...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British journal of ophthalmology >Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema
【24h】

Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema

机译：玻璃体腔注射贝伐单抗，兰尼单抗和培加他尼前后玻璃体内注射与年龄相关性黄斑变性患者和糖尿病性黄斑水肿患者血浆中血管内皮生长因子的水平

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims: To determine the level of vascular endothelial growth factor (VEGF) in the plasma of patients with diabetic macular edema (DME) and of patients with exudative age-related macular degeneration (ARMD) before and after intravitreal injection of bevacizumab, ranibizumab or pegaptanib. Methods: 30 patients with DME and 30 patients with ARMD were included in this randomized controlled study. Patients were randomized to treatment with ranibizumab (0.5 mg), bevacizumab (1.25 mg) or pegaptanib (0.3 mg). 10 patients with DME received bevacizumab, 10 ranibizumab and 10 pegaptanib. The same randomized treatment allocation applied to the 30 patients with ARMD. The concentrations of VEGF were measured by ELISA just before the injection, after 7 days and 1 month. Results: Plasma VEGF in patients with exudative ARMD before the injection of bevacizumab was 89.7 pg/ml. It was significantly reduced to 25.1 pg/ml after 7 days ( p=0.01), and to 22.8 pg/ml after 1 month (p=0.008). In patients with DME the same systemic reduction by bevacizumab was observed with a significant decrease of baseline VEGF level from 72.2 pg/ml to 13.7 pg/ml after 7 days (p=0.008) and 17.1 pg/ml at 4 weeks with (p=0.012). No significant reductions of plasma VEGF levels were observed in patients receiving ranibizumab or pegaptanib during follow-up. Conclusions: Bevacizumab significantly reduces the level of VEGF in the blood plasma for up to one month in patients with DME as well as in those with ARMD. No significant systemic effects of intravitreal ranibizumab or pegaptanib on plasma VEGF could be observed.
机译：目的：确定在玻璃体内注射贝伐单抗，兰尼单抗或培加他尼之前和之后，糖尿病性黄斑水肿（DME）和渗出性年龄相关性黄斑变性（ARMD）患者血浆中的血管内皮生长因子（VEGF）水平。方法：该随机对照研究包括30例DME患者和30例ARMD患者。患者被随机分配接受兰尼单抗（0.5 mg），贝伐单抗（1.25 mg）或培加他尼（0.3 mg）治疗。 10例DME患者接受了贝伐单抗，10尼珠单抗和10例培加他尼治疗。相同的随机治疗分配适用于30名ARMD患者。在注射前，7天和1个月后，通过ELISA测量VEGF的浓度。结果：注射贝伐单抗前渗出性ARMD患者的血浆VEGF为89.7 pg / ml。 7天后显着降低至25.1 pg / ml（p = 0.01），1个月后显着降低至22.8 pg / ml（p = 0.008）。在DME患者中，观察到贝伐单抗的全身性降低，在7天后（p = 0.008），基线VEGF水平从72.2 pg / ml显着降低至13.7 pg / ml，在4周时降低了17.1 pg / ml，其中（p = 0.012）。在随访期间，接受雷珠单抗或培加他尼治疗的患者血浆VEGF水平未见明显降低。结论：贝伐单抗可显着降低DME和ARMD患者血浆中VEGF的水平，长达一个月。没有观察到玻璃体内雷珠单抗或培加他尼对血浆VEGF的显着全身作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号